- AquaBounty Technologies, Inc. Announces Proposed Public Offering of $10.0 Million of Common Stock
- Adverum Biotechnologies Moves to New Headquarters and Expands Laboratory Space in Redwood City, CA
- Tocotrienols Market To Reach USD 522.0 Million By 2026| Reports And Data
- CytoDyn Abstract by Dr. Jonah Sacha for Use of Leronlimab as PrEP is Accepted by the Keystone Symposia on HIV Pathogenesis and Cure
- RedHill Biopharma Launches H. pylori Disease State Awareness Field Campaign Ahead of Talicia® Launch
- CytoDyn Announces CROI’s Acceptance of Late-Breaking Abstract by Dr. Jonah Sacha for use of Leronlimab as PrEP
- Announcement of Request for Delisting of Veloxis Pharmaceuticals A/S' Shares from Nasdaq Copenhagen
- Offentliggørelse af Anmodning om Afnotering af Veloxis Pharmaceuticals A/S' Aktier fra Nasdaq Copenhagen A/S
- Notice on Compulsory Acquisition to the Shareholders of Veloxis Pharmaceuticals A/S
- Meddelelse om Tvangsindløsning til Aktionærerne i Veloxis Pharmaceuticals A/S
